#United States #Rockville #gene therapy #biotechnology #REGENXBIO

REGENXBIO to Attend Upcoming Investor Conferences

REGENXBIO Inc. (Nasdaq: RGNX), a pioneering biotechnology company specializing in gene therapy, has announced its schedule for upcoming investor conferences in 2025. These events are crucial opportunities for the company to engage with investors, share advancements in their clinical pipeline, and discuss the future of gene therapy.

Conference Details

REGENXBIO will participate in five significant investor conferences across various locations, highlighting its commitment to transparency and investor relations. The details of the conferences are as follows:

1. BofA Securities Health Care Conference 2025

• - Date: Tuesday, May 13, 2025
• - Time: 5:00 PM PT
• - Location: Las Vegas, NV

2. RBC Global Healthcare Conference

• - Date: Tuesday, May 20, 2025
• - Time: 11:30 AM ET
• - Location: New York, NY
• - Format: Fireside Chat

3. H.C. Wainwright BioConnect

• - Date: Tuesday, May 20, 2025
• - Time: 4:00 PM ET
• - Location: New York, NY
• - Format: Fireside Chat

4. Stifel Virtual Ophthalmology Forum

• - Date: Tuesday, May 27, 2025
• - Time: 9:30 AM ET
• - Format: Virtual Fireside Chat

5. UBS Spring Biotech Conference

• - Date: Tuesday, June 24, 2025
• - Location: New York, NY
• - Format: 1x1 Investor Meetings

Investors will have access to live webcasts of some of the presentations and chats, with archived replays available for approximately 30 days post-event. Interested parties can find further details in the Investors section of REGENXBIO's official website.

About REGENXBIO Inc.

Founded in 2009, REGENXBIO has been at the forefront of gene therapy, particularly through its AAV (adeno-associated virus) gene therapy platform. The company's mission is to enhance lives by employing the curative potential of gene therapy to treat a variety of diseases. Among its notable developments are therapies targeting rare genetic and retinal conditions, including:

• - RGX-202: A one-time treatment aimed at addressing Duchenne Muscular Dystrophy.
• - Clemidsogene lanparvovec (RGX-121): A therapy focused on Mucopolysaccharidosis Type II (MPS II), developed in collaboration with Nippon Shinyaku.
• - RGX-111: Designed for MPS I, also in partnership with Nippon Shinyaku.
• - Suragene lomparvovec (ABBV-RGX-314): Targeting wet age-related macular degeneration and diabetic retinopathy, developed in collaboration with AbbVie.

REGENXBIO's innovative therapies have the potential to redefine healthcare delivery for millions. Thousands of patients have already benefitted from its AAV platform, which is also used in conjunction with Novartis' ZOLGENSMA, a leading gene therapy for spinal muscular atrophy.

As REGENXBIO continues to advance its pipeline and mission, these upcoming conferences present a vital platform for the exchange of knowledge and fostering relationships with the investment community. By sharing their progress and insights at these events, REGENXBIO aims to strengthen its position in the biotechnology sector and highlight the transformative potential of its gene therapies.

Contact Information

For further inquiries, REGENXBIO can be reached through its corporate communications and investor relations contacts:

• - Dana Cormack

Corporate Communications
email

• - George E. MacDougall

Investor Relations
email

For more information, please visit www.regenxbio.com.